mitomycin

Notably, the membrane maintained cell viability for both urothelial cells and smooth muscle cells over 7 days, confirming its biocompatibility. These findings highlight the promising potential of the PLLA/GEL/MMC microfiber membrane not only as a material for bladder tissue engineering but also as a tool for therapeutic intervention that addresses multiple facets of bladder healing and regeneration.

Hence, CRISPR-Select is an important tool for efficient variant clinical classification. Application of this technology in the future will ultimately improve patient care.

P2, N=107, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed

P3, N=220, Not yet recruiting, Janssen Research & Development, LLC

P1, N=50, Recruiting, Cardiff University | Phase classification: P1b --> P1 | Trial completion date: Nov 2022 --> Nov 2026 | Trial primary completion date: Nov 2022 --> Nov 2026

P=N/A, N=96, Completed, Beijing Hospital; Beijing Hospital

Approved therapies for refractory mCRC, including regorafenib, trifluridine/tipiracil (FTD/TPI), and fruquintinib, demonstrate modest survival benefits but are often associated with significant toxicities...The potential of rechallenge strategies using previously administered therapies, such as oxaliplatin and anti-EGFR agents, is examined, supported by retrospective and prospective studies. Furthermore, the role of older drugs like mitomycin C in combination with capecitabine is revisited, offering insights into their viability in advanced treatment settings. Ongoing clinical trials with novel agents and combinations are expected to provide further clarity on optimizing sequential treatment regimens and personalizing therapy for mCRC patients. This review emphasizes the need for comprehensive molecular profiling and shared decision-making to improve outcomes and quality of life in this challenging patient population.

This study evaluated the outcomes of selective intra-arterial mitomycin-C infusions in combination with bi-weekly systemic irinotecan for treatment of liver-dominant metastatic colorectal cancer (CRC) which progressed after hepatic arterial infusion (HAI) pump chemotherapy with floxuridine and at least two lines of systemic chemotherapy. In this heavily pretreated population, addition of intra-arterial mitomycin-C was associated with initial liver disease control rates exceeding 80%. Toxicities were observed, particularly in patients with prolonged disease control who received ≥4 infusions.

Moreover, in the context of extraocular surgeries, specific agents such as mitomycin C (MMC), interferon (IFN) alpha-2b, and 5-fluorouracil serve unique roles extending beyond infection prevention. IFN alpha-2b, with its antiviral and antiproliferative properties, is utilized to decrease the recurrence of conjunctival and corneal neoplasias postoperatively. This review examines the current understanding of prophylactic antibiotic use in certain extraocular surgeries and the role of antibiotics and some specific agents in enhancing surgical outcomes.

In the group with high CDH18 expression, the IC50 values for (5Z)-7-Oxozeaenol, AG-014699, CEP-701, Mitomycin C, PD-0325901, PD-0332991, PHA-665752, SL 0101-1, and SN-38 were notably elevated. CDH18 is a novel promising biomarker in UCEC, uniquely associating tumor progression, immune modulation, and chemotherapy resistance, offering enhanced prognostic accuracy and guiding individualized therapeutic strategies for improved patient outcomes.

P1, N=10, Recruiting, West Virginia University | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Dec 2024 --> Dec 2027

The platinum-resistance-related gene signature (SLC22A2, TAP1, PC, MCM3, GTF2H2, FXYD5, SUPT6H, IGKC, and MATN2) is valuable for prognosis prediction and guidance of treatment choices for OC patients.

In its absence, human cells exhibit greater sensitivity towards anti-cancer drugs such as mitomycin C and camptothecin...These findings suggest a potential role for ZGRF1 in the proliferation of specific cancer types, highlighting avenues for further research in other cancer models. Additionally, beyond its known function in DNA repair, our study also reveals that ZGRF1 promotes meiotic recombination and that its loss results in reduced fertility in mice manifested as a 30 % reduction in meiotic crossovers and a 15 % reduction in litter size.

Lastly, our high-throughput, single-organoid-resolution drug screens unexpectedly revealed PIK3CA -driven organoids exhibited sensitivity to Mitomycin C and Onalespib. This study provides novel mechanistic insights into early neoplastic evolution and underscores the value of genetically-defined organoid models for investigating cancer biology and identifying targeted therapies.

P3, N=1083, Not yet recruiting, Maimónides Biomedical Research Institute of Córdoba

EPI combined with mindfulness intervention significantly improved clinical outcomes in patients with urinary system tumors and depression and is worthy of clinical application.

P=N/A, N=180, Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College ,Huazhong University o

P=N/A, N=40, Completed, Eye and ENT Hospital of Fudan University; Eye and ENT Hospital of Fudan University

Our prognostic model can effectively predict outcomes and facilitate stratification GC patients, offering valuable insights for clinical decision-making. The identified transcription factor MEF2C can serve as a biomarker for assessing the efficacy of immunotherapy for GC.

P2, N=1460, Active, not recruiting, UNICANCER | Trial completion date: Dec 2024 --> Dec 2025

P2, N=40, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2025 --> May 2026

P3, N=340, Terminated, Alliance for Clinical Trials in Oncology | Unknown status --> Terminated

Notably, the half-maximal inhibitory concentration (IC50) of commonly used chemotherapeutic drugs, such as lapatinib and mitomycin, was inversely associated with TRAF3IP3 expression in HCC patients. TRAF3IP3 may be as a novel and promising biomarker for prognosis prediction and immunological evaluation of HCC.

P3, N=176, Recruiting, University of Southampton | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Dec 2024

CD8RGs play an important role in regulating the TME of PAAD. Five hub genes-BCL11A, KLK11, GNG7, PHOSPHO1, and VCAM1-are closely associated with the prognosis of PAAD patients, providing new references for the exploration of biomarkers. Furthermore, our findings offer novel insights for clinical decision-making.

P3, N=520, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2031 --> Nov 2031

Interestingly, both patients had negative results on the initial chromosomal breakage test with mitomycin C, a commonly used diagnostic tool for FA...Molecular genetic testing, such as WES, can provide a definitive diagnosis and guide appropriate management strategies. Early and accurate diagnosis is crucial for improving outcomes in individuals with this potentially fatal illness, as promising advancements in treatments such as hematopoietic stem cell transplantation and gene therapy offer hope for addressing FA.

P3, N=144, Not yet recruiting, St. Joseph's Healthcare Hamilton

P3, N=520, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2029 --> Jan 2027

P2, N=51, Completed, Albert Einstein College of Medicine | Trial completion date: Nov 2020 --> Aug 2024

High-risk patients were more responsive to cisplatin, doxorubicin, and mitomycin C, while low-risk patients were more sensitive to erlotinib. We have developed a prognostic model with m5C/m6A/m7G-related NARCD genes to predict the prognosis of HCC patients. This model can offer insights into the effectiveness of immunotherapy and chemotherapy for HCC patients.

P4, N=216, Recruiting, Hospital Universitario de Fuenlabrada | Trial completion date: Jan 2027 --> Oct 2029 | Trial primary completion date: Jan 2027 --> Oct 2029

Drug screening using mitomycin-C (MMC), 5-fluorouricil (5-FU), and 6-Diazo-5-oxo-L-norleucine (DON) were performed...Ocular adnexal SebCA cell lines can be established using conditional reprogramming cell conditions, and our three new models are useful for testing therapies and interrogating the functional role of MYC and other possible molecular drivers. Current topical chemotherapies promote both apoptosis and differentiation in SebCA cells, and these tumors appear sensitive to inhibition or MYC-associated metabolic changes.

CRC patients with high-risk score more sensitive to docetaxel and rapamycin but resistance to gemcitabine and mitomycin. In the study, a PRGs-based prognostic model and a predictive model were constructed. These models are effective and robust in prediction the 1-, 3-, and 5-year survival of CRC patients.

P2, N=27, Completed, National Cancer Institute (NCI) | Trial completion date: Oct 2027 --> Jul 2024 | Trial primary completion date: Oct 2025 --> Apr 2024 | Active, not recruiting --> Completed

P2, N=71, Active, not recruiting, Centre Francois Baclesse | Trial completion date: Dec 2023 --> Dec 2024

P2, N=21, Recruiting, University of Chicago | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026

P2, N=48, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jun 2024 --> Jun 2025

P3, N=176, Not yet recruiting, University of Southampton

Four cycles of mitomycin C (0.02%) were administered as chemoadjuvant therapy...In most cases, wide surgical excision is sufficient. In addition, adjuvant therapies may be beneficial in preventing tumor recurrence.

Although type I IFNs cause direct toxicity on corneal cells, they do not induce significant side effects on the healthy ocular surface. Considering its therapeutic and preventive effects, topical type I IFN is safe and effective for treating ocular surface tumors. The potential for ocular side effects should be considered in eyes with identified risk factors.

BRAF mutations were frequently detected and were associated with particularly poor survival in this cohort, possibly related to ligand-dependent Wnt activation and altered drug transport and metabolism that could confer resistance to MMC and irinotecan. Drugs that target ligand-dependent Wnt activation or the BTN immune checkpoints could represent two novel therapy approaches.